

APPENDIX 1

MARKED-UP VERSION OF THE CLAIMS

12 (Amended). A process for the production of a compound of formula (1) as define in [any one of claims] claim 1 [to 11], or a pharmaceutically acceptable salt thereof, comprising cultivating a strain of a microorganism capable of producing a compound of formula (1), recovering the compound of formula (1) from the cultured broth , and, optionally, salifying the recovered compound.

15 (Amended). A pharmaceutical composition containing as an active ingredient a compound of formula (1) as define in [any one of claims] claim 1 [to 11], or a pharmaceutically acceptable salt thereof, in conjunction with a pharmaceutically acceptable carrier or diluent.

16 (Amended). A compound of formula (1) as defined in [any one of claims] claim 1 [to 11], or a pharmaceutically acceptable salt thereof for use as a medicament.

17 (Amended). The use of a compound of formula (1) as defined in [any one of claims] claim 1 [to 11], or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of malignant tumours in a mammal.

18 (Amended). A method for the treatment or prophylaxis of malignant tumours in a mammal, comprising administering to a mammal in need of such treatment an effective amount of a

Docket No. 211-213

compound of formula (1) as defined in [any one of claims] claim 1 [to 11], or a pharmaceutically acceptable salt thereof.

20250000-0204-001